Mesenchymal stromal cells: A promising cell source for the treatment of inflammatory cardiomyopathy

Current Pharmaceutical Design

Volumn 17, Issue 30, 2011, Pages 3295-3307

  Tschope C ^a   Miteva, K ^a   Schultheiss, H P ^a   van Linthout, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Administration route; Cell origin; Cytokines; Homing; Inflammatory cardiomyopathy; Mesenchymal stromal cells

Indexed keywords

5' NUCLEOTIDASE; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; ENDOGLIN; ESTROGEN; FIBROBLAST GROWTH FACTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HLA DR ANTIGEN; INTEGRIN LINKED KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1ALPHA; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

ADIPOSE TISSUE; ALLOGENEIC STEM CELL TRANSPLANTATION; AMNION; AMNION FLUID; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CARDIOMYOPATHY; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL HOMING; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; ENGRAFTMENT; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPOXIA; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CARDIOMYOPATHY; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; NONHUMAN; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UMBILICAL CORD BLOOD;

EID: 80055098011     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797904136     Document Type: Review

References (215)

1. Karjalainen J, Heikkilä J. Incidence of three presentations of acute myocarditis in young men in military service. a 20-year experience. Eur Heart J 1999; 20: 1120-25.
2. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-{beta} treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-98.
3. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virusnegative inflammatory cardiomyopathy: the timic study. European Heart Journal 2009; 30: 1995-2002.
4. Staudt A, Herda LR, Trimpert C, et al. Fcgamma-receptor iia polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin Pharmacol. Ther 2010; 87: 452-58.
5. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
6. Van Linthout S, Savvatis K, Miteva K, et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2010.
7. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005; 112: 1128-35.
8. Ohnishi S, Yanagawa B, Tanaka K, et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J. Mol Cell Cardiol 2007; 42: 88-97.
9. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
10. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4: 267-74.
11. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement. Cytotherapy 2006; 8: 315-17.
12. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 2003; 100 Suppl 1: 11917-23.
13. Drost AC, Weng S, Feil G, et al. In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann NY Acad Sci 2009; 1176: 135-43.
14. Kuo CK, Tuan RS. Mechanoactive tenogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A 2008; 14: 1615-27.
15. Mannello F, Tonti GAM, Bagnara GP, Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006; 24: 475-81.
16. Shakhbazov AV, Kosmacheva SM, Kartel' NA, Potapnev MP. [neurogenic differentiation of mesenchymal stem cells: a transgenic approach]. Tsitologiia 2010; 52: 301-04.
17. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198: 54-64.
18. Tormin A, Brune JC, Olsson E, et al. Characterization of bone marrow-derived mesenchymal stromal cells (msc) based on gene expression profiling of functionally defined msc subsets. Cytotherapy 2009; 11: 114-28.
19. Peiffer I, Eid P, Barbet R, et al. A sub-population of high proliferative potential-quiescent human mesenchymal stem cells is under the reversible control of interferon alpha/beta. Leukemia 2007; 21: 714-24.
20. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J. Cell Mol Med 2004; 8: 301-16.
21. Krinner A, Hoffmann M, Loeffler M, Drasdo D, Galle J. Individual fates of mesenchymal stem cells in vitro. BMC Syst Biol 2010; 4: 73.
22. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009; 11: 377-91.
23. Huang X-P, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010; 122: 2419-29.
24. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences 2009; 106: 14022-27.
25. Nguyen B-K, Maltais S, Perrault LP, et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res 2010; 3: 547-58.
26. Mias C, Lairez O, Trouche E, et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009; 27: 2734-43.
27. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Letters 2007; 581: 3961-66.
28. Li L, Zhang Y, Li Y, et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl. Int 2008; 21: 1181-89.
29. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-26.
30. Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress b-cell terminal differentiation. Experimental Hematology 2009; 37: 604-15.
31. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress t-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-43.
32. English K, Barry FP, Field-Corbett CP, Mahon BP. Ifn-gamma and tnf-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett 2007; 110: 91-100.
33. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human th17 cell differentiation and function and induce a t regulatory cell phenotype. J. Immunol 2010; 185: 302-12.
34. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
35. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
36. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-506.
37. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic t-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-21.
38. Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via stat3 signaling. Experimental Hematology 2007; 35: 426-33.
39. Sheng H, Wang Y, Jin Y, et al. A critical role of ifn[gamma] in priming msc-mediated suppression of t cell proliferation through up-regulation of b7-h1. Cell Res 2008; 18: 846-57.
40. Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. The J Immunology 2010; 184: 2321-28.
41. Xu G, Zhang Y, Zhang L, Ren G, Shi Y. The role of il-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochemical and Biophysical Research Communications 2007; 361: 745-50.
42. Woodruff JF, Woodruff JJ. Involvement of t lymphocytes in the pathogenesis of coxsackie virus b3 heart disease. J. Immunol 1974; 113: 1726-34.
43. Rangachari M, Mauermann N, Marty RR, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J. Exp Med 2006; 203: 2009-19.
44. Yuan J, Yu M, Lin QW, et al. Neutralization of il-17 inhibits the production of anti-ant autoantibodies in cvb3-induced acute viral myocarditis. Int. Immunopharmacol 2010; 10: 272-76.
45. Shi Y, Fukuoka M, Li G, et al. Regulatory t cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation 2010; 121: 2624-34.
46. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678-85.
47. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of placental-derived adherent stromal cell (plx-pad) in the treatment of critical limb ischemia. Cytotherapy 2009; 11: 427-34.
48. Li W, Ma N, Ong LL, et al. Bcl-2 engineered mscs inhibited apoptosis and improved heart function. Stem Cells 2007; 25: 2118-27.
49. Nagaya N, Fujii T, Iwase T, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiology Heart and Circulatory Physiology 2004; 287: H2670-76.
50. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol. Diabetes 2008; 116: 104-11.
51. Li JH, Zhang N, Wang JA. Improved anti-apoptotic and antiremodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J. Endocrinol. Invest 2008; 31: 103-10.
52. Yue WM, Liu W, Bi YW, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. Stem Cells and Development 2008; 17: 785-94.
53. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678-85.
54. Ohnishi S, Yasuda T, Kitamura S, Nagaya N. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 2007; 25: 1166-77.
55. Hung S-C, Pochampally RR, Chen S-C, Hsu S-C, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the pi3k-akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007; 25: 2363-70.
56. Oswald J, Boxberger S, Jørgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004; 22: 377-84.
57. Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2007; 20: 867-76.
58. Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with cd146+ perivascular cells and fibroblasts. Experimental Hemato 2008; 36: 642-54.
59. Schuleri KH, Amado LC, Boyle AJ, et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiology Heart and Circulatory Physiol 2008; 294: H2002-11.
60. Hahn JY, Cho HJ, Kang HJ, et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008; 51: 933-43.
61. Xiang M-xiang, He A-na, Wang J-an, Gui C. Protective paracrine effect of mesenchymal stem cells on cardiomyocytes. J Zhejiang Univ Sci B 2009; 10: 619-24.
62. Nakanishi C, Yamagishi M, Yamahara K, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun 2008; 374: 11-6.
63. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107: 913-22.
64. Armiñán A, Gandía C, García-Verdugo JM, et al. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. J. Am Coll Cardiol 2010; 55: 2244-53.
65. Iwase T, Nagaya N, Fujii T, et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovascular Res 2005; 66: 543-51.
66. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-34.
67. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 2004; 19: 1450-56.
68. Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 2006; 74: 545-51.
69. Ochsenbein-Kölble N, Bilic G, Hall H, Huch R, Zimmermann R. Inducing proliferation of human amnion epithelial and mesenchymal cells for prospective engineering of membrane repair. J Perinat Med 2003; 31: 287-94.
70. Portmann-Lanz CB, Schoeberlein A, Huber A, et al. Placental mesenchymal stem cells as potential autologous graft for preand perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664-73.
71. Kim JW, Kim SY, Park SY, et al. Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol 2004; 83: 733-8.
72. Fu YS, Cheng YC, Lin MYA, et al. Conversion of human umbilical cord mesenchymal stem cells in wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for parkinsonism. Stem Cells 2006; 24: 115-24.
73. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-95.
74. Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. Curr. Opin. Mol Ther 2005; 7: 300-5.
75. Mareschi K, Biasin E, Piacibello W, Aglietta M, Madon E, Fagioli F. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001; 86: 1099-100.
76. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-28.
77. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-16.
78. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-301.
79. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-34.
80. Musina RA, Bekchanova ES, Sukhikh GT. Comparison of mesenchymal stem cells obtained from different human tissues. Bull. Exp Biol Med 2005; 139: 504-9.
81. Dicker A, Le Blanc K, Aström G, et al. Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res 2005; 308: 283-90.
82. Sudo K, Kanno M, Miharada K, et al. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. Stem Cells 2007; 25: 1610-17.
83. Tsai MS, Hwang SM, Chen KD, et al. Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells 2007; 25: 2511-23.
84. Packard M, Koo ES, Gorczyca M, Sharpe J, Cumberledge S, Budnik V. The drosophila wnt, wingless, provides an essential signal for preand postsynaptic differentiation. Cell 2002; 111: 319-30.
85. Petropoulos H, Skerjanc IS. Beta-catenin is essential and sufficient for skeletal myogenesis in p19 cells. J Biol Chem 2002; 277: 15393-99.
86. Pandur P, Läsche M, Eisenberg LM, Kühl M. Wnt-11 activation of a non-canonical wnt signalling pathway is required for cardiogenesis. Nature 2002; 418: 636-41.
87. Liu T, Lee YN, Malbon CC, Wang Hyu. Activation of the betacatenin/lef-tcf pathway is obligate for formation of primitive endoderm by mouse f9 totipotent teratocarcinoma cells in response to retinoic acid. J Biol Chem 2002; 277: 30887-91.
88. Fischer L, Boland G, Tuan RS. Wnt signaling during bmp-2 stimulation of mesenchymal chondrogenesis. J Cell Biochem 2002; 84: 816-31.
89. Lee RH, Kim B, Choi I, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 2004; 14: 311-24.
90. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-301.
91. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006; 98: 1414-21.
92. Duff SE, Li C, Garland JM, Kumar S. Cd105 is important for angiogenesis: evidence and potential applications. Faseb J 2003; 17: 984-92.
93. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CPH, Bernabéu C. Endoglin regulates cytoskeletal organization through binding to zrp-1, a member of the lim family of proteins. J Biol Chem 2004; 279: 32858-68.
94. Gaebel R, Furlani D, Sorg H, et al. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS ONE 2011; 6: e15652.
95. Dai Y, Ashraf M, Zuo S, et al. Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair. J Mol Cell Cardiol 2008; 44: 607-17.
96. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-98.
97. Sorrell JM, Baber MA, Caplan AI. Influence of adult mesenchymal stem cells on in vitro vascular formation. Tissue Engineering Part A 2009; 15: 1751-61.
98. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705.
99. Xu W, Zhang X, Qian H, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004; 229: 623-31.
100. Rangappa S, Fen C, Lee EH, Bongso A, Sim EKW, Wei EKS. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003; 75: 775-9.
101. Planat-Bénard V, Menard C, André M, et al. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 2004; 94: 223-29.
102. Rangappa S, Fen C, Lee EH, Bongso A, Sim EKW, Wei EKS. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003; 75: 775-79.
103. Song Y-H, Gehmert S, Sadat S, et al. Vegf is critical for spontaneous differentiation of stem cells into cardiomyocytes. Biochem Biophys Res Commun 2007; 354: 999-1003.
104. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-37.
105. Carr BI, Reilly JG, Smith SS, Winberg C, Riggs A. The tumorigenicity of 5-azacytidine in the male fischer rat. Carcinogenesis 1984; 5: 1583-90.
106. Deuse T, Stubbendorff M, Tang-Quan K, et al. mmunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 2010.
107. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord wharton's jelly-derived cells. Stem Cells 2008; 26: 2865-74.
108. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesissupportive function and other potentials. Haematologica 2006; 91: 1017-26.
109. Hoogduijn MJ, Crop MJ, Peeters AMA, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16: 597-604.
110. Niemeyer P, Kornacker M, Mehlhorn A, et al. Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng 2007; 13: 111-21.
111. Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adiposederived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin e2. Tissue Eng 2007; 13: 1185-95.
112. McIntosh K, Zvonic S, Garrett S, et al. The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells 2006; 24: 1246-53.
113. Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005; 129: 118-29.
114. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing tcell anergy. Blood 2005; 106: 1755-61.
115. Constantin G, Marconi S, Rossi B, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27: 2624-35.
116. Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Letters 2009; 126: 37-42.
117. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
118. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
119. Sheng H, Wang Y, Jin Y, et al. A critical role of ifngamma in priming msc-mediated suppression of t cell proliferation through up-regulation of b7-h1. Cell Res 2008; 18: 846-57.
120. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-63.
121. Sheng H, Wang Y, Jin Y, et al. A critical role of ifngamma in priming msc-mediated suppression of t cell proliferation through up-regulation of b7-h1. Cell Res 2008; 18: 846-57.
122. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57.
123. Böcker W, Docheva D, Prall WC, et al. Ikk-2 is required for tnfalpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med 2008; 86: 1183-92.
124. Miettinen JA, Pietilä M, Salonen RJ, et al. Tumor necrosis factor alpha promotes the expression of immunosuppressive proteins and enhances the cell growth in a human bone marrow-derived stem cell culture. Exp Cell Res 2011; 317: 791-801.
125. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Proinflammatory cytokines, ifngamma and tnfalpha, influence immune properties of human bone marrow and wharton jelly mesenchymal stem cells differentially. PLoS ONE 2010; 5: e9016.
126. Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J. Immunol 2010; 184: 2321-28.
127. Djouad F, Fritz V, Apparailly F, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005; 52: 1595-603.
128. Bao C, Guo J, Lin G, Hu M, Hu Z. Tnfr gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following mi. Scand. Cardiovasc J 2008; 42: 56-62.
129. Lombardo E, DelaRosa O, Mancheño-Corvo P, Menta R, Ramírez C, Büscher D. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 2009; 15: 1579-89.
130. Augello A, Tasso R, Negrini SM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-90.
131. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of t-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-34.
132. Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase r. Stem Cells 2009; 27: 909-19.
133. Hwa Cho H, Bae YC, Jung JS. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 2006; 24: 2744-52.
134. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-32.
135. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26: 99-107.
136. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (msc) paradigm: polarization into a proinflammatory msc1 or an immunosuppressive msc2 phenotype. PLoS ONE 2010; 5: e10088.
137. Romieu-Mourez R, François M, Boivin M-N, Bouchentouf M, Spaner DE, Galipeau J. Cytokine modulation of tlr expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-73.
138. Verreck FAW, de Boer T, Langenberg DML, van der Zanden L, Ottenhoff THM. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and ifnand cd40l-mediated costimulation. J Leukocyte Biology 2006; 79: 285-93.
139. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hmscs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein tsg-6. Cell Stem Cell 2009; 5: 54-63.
140. Németh K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin e(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-9.
141. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010; 107: 913-22.
142. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-49.
143. Van Linthout S, Stamm C, Schultheiss HP, Tschöpe C. Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond. Cardiol Res Pract 2011: 757154.
144. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-45.
145. Ringe J, Strassburg S, Neumann K, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors cxcr1, cxcr2 and ccr2, and migrate upon stimulation with cxcl8 but not ccl2. J Cell Biochem 2007; 101: 135-46.
146. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-41.
147. Zhu N, Zhang D, Chen S, et al. Endothelial enriched micrornas regulate angiotensin ii-induced endothelial inflammation and migration. Atherosclerosis 2011; 215:286-93.
148. Behr TM, Wang X, Aiyar N, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000; 102:1315-22.
149. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1{alpha} plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110: 3300-5.
150. Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007; 25: 245-51.
151. Shen Y, Xu W, Chu YW, Wang Y, Liu Q-S, Xiong SD. Coxsackievirus group b type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol 2004; 78: 12548-56.
152. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin ii receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994; 90: 2051-55.
153. Chu PY, Mariani J, Finch S, et al. Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 2010; 176: 1735-42.
154. Omura T, Yoshiyama M, Kim S, et al. Involvement of apoptosis signal-regulating kinase-1 on angiotensin ii-induced monocyte chemoattractant protein-1 expression. Arterioscler. Thromb Vasc Biol 2004; 24: 270-75.
155. Zhang D, Fan GC, Zhou X, et al. Over-expression of cxcr4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 2008; 44: 281-92.
156. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient homing of multipotent adult mesenchymal stem cells depends on frount-mediated clustering of ccr2. Cell Stem Cell 2008; 2: 566-75.
157. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active cxcr4 receptor capable of promoting migration to bone marrow. Blood 2004; 104: 2643-45.
158. Shi M, Li J, Liao L, et al. Regulation of cxcr4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in nod/scid mice. Haematologica 2007; 92: 897-904.
159. Croitoru-Lamoury J, Lamoury FMJ, Zaunders JJ, Veas LA, Brew BJ. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, ifn-, and copaxone. J Interferon Cytokine Res 2007; 27: 53-64.
160. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem cells 2007; 25: 1737-45.
161. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108: 3938-44.
162. Fox JM, Chamberlain G, Ashton BA, Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. Br. J Haematol 2007; 137: 491-502.
163. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678-89.
164. Peled A, Kollet O, Ponomaryov T, et al. The chemokine sdf-1 activates the integrins lfa-1, vla-4, and vla-5 on immature human cd34(+) cells: role in transendothelial/stromal migration and engraftment of nod/scid mice. Blood 2000; 95: 3289-96.
165. Krampera M, Pizzolo G, Aprili G, Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 2006; 39: 678-83.
166. Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Molecular and Cellular Cardiology 2008; 44: 1072-84.
167. De Becker A, Van Hummelen P, Bakkus M, et al. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 2007; 92: 440-49.
168. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. Mmp-2, mt1-mmp, and timp-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007; 109: 4055-63.
169. Schweitzer KM, Dräger AM, van der Valk P, et al. Constitutive expression of e-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol 1996; 148:165-75.
170. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-201.
171. Kim YS, Park HJ, Hong MH, et al. Tnf-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci 2009; 14: 2845-56.
172. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by tnf-alpha, lps, or hypoxia produce growth factors by an nf kappa bbut not jnkdependent mechanism. Am J Physiol Cell Physiol 2008; 294: C675-82.
173. Bao C, Guo J, Zheng M, Chen Y, Lin G, Hu M. Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by tnfr gene transfection. Biochem Cell Biol 2010; 88:629-34.
174. Tan J, Weil BR, Abarbanell AM, et al. Ablation of tnf-alpha receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. Shock 2010; 34: 236-42.
175. Tan J, Weil BR, Abarbanell AM, et al. Ablation of tnf-alpha receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. Shock 2010; 34: 236-42.
176. Fairweather D, Frisancho-Kiss S, Yusung SA, et al. Interferongamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 2004; 165: 1883-94.
177. Wu GD, Nolta JA, Jin YS, et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003; 75: 679-85.
178. Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proceedings of the National Academy of Sciences 2002; 99: 8932-37.
179. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27: 1114-22.
180. Shen Y, Xu W, Chu Y-W, Wang Y, Liu QS, Xiong S-D. Coxsackievirus group b type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J. Virol 2004; 78: 12548-56.
181. Leuschner F, Panizzi P, Chico-Calero I, et al. Angiotensinconverting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ Res 2010; 107: 1364-73.
182. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hmscs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein tsg-6. Cell Stem Cell 2009; 5: 54-63.
183. Beeres SLMA, Bax JJ, Zeppenfeld K, et al. Feasibility of transendocardial cell transplantation in chronic ischaemia. Heart 2007; 93: 113-14.
184. Perin EC, Silva GV, Assad JAR, et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Molecular and Cellular Cardiology 2008; 44: 486-95.
185. Ladage D, Turnbull IC, Ishikawa K, et al. Delivery of gelfoamenabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 2011.
186. Hare JM. Translational development of mesenchymal stem cell therapy for cardiovascular diseases. Tex Heart Inst J 2009; 36: 145-47.
187. Sanz-Ruiz R, Santos MEF, Muñoa MD, et al. Adipose tissuederived stem cells: the friendly side of a classic cardiovascular foe. J Cardiovasc Transl Res 2008; 1: 55-63.
188. Dai W, Hale SL, Kay GL, Jyrala AJ, Kloner RA. Delivering stem cells to the heart in a collagen matrix reduces relocation of cells to other organs as assessed by nanoparticle technology. Regen Med 2009; 4: 387-95.
189. Gnecchi M, He H, Melo LG, et al. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing akt on cardiac metabolism after myocardial infarction. Stem Cells 2009; 27: 971-79.
190. Song H, Kwon K, Lim S, et al. Transfection of mesenchymal stem cells with the fgf-2 gene improves their survival under hypoxic conditions. Mol Cells 2005; 19: 402-7.
191. Markel TA, Wang Y, Herrmann JL, et al. Vegf is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008; 295: H2308-14.
192. Lian WS, Cheng WTK, Cheng CC, et al. In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin i synthase gene improves cardiac performance in mice. Life Sci 2011; 88:455-64.
193. Chang W, Song B-W, Lim S, et al. Mesenchymal stem cells pretreated with delivered hph-1-hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 2009; 27: 2283-92.
194. Song H, Chang W, Lim S, et al. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 2007; 25:1431-38.
195. Song S-W, Chang W, Song B-W, et al. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cells 2009; 27:1358-65.
196. Tang J, Wang J, Guo L, et al. Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol Cells 2010; 29: 9-19.
197. Tang J, Wang J, Yang J, et al. Mesenchymal stem cells overexpressing sdf-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg 2009; 36:644-50.
198. Cho J, Zhai P, Maejima Y, Sadoshima J. Myocardial injection with gsk-3 -overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 2011; 108: 478-89.
199. Bao C, Guo J, Zheng M, Chen Y, Lin G, Hu M. Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by tnfr gene transfection. Biochem Cell Biol 2010; 88: 629-34.
200. Ray R, Novotny NM, Crisostomo PR, Lahm T, Abarbanell A, Meldrum DR. Sex steroids and stem cell function. Mol Med 2008; 14: 493-501.
201. Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in postinfarct swine hearts. Eur Heart J 2008; 29: 1578-90.
202. Lu G, Haider HK, Jiang S, Ashraf M. Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioninginduced connexin-43. Circulation 2009; 119: 2587-96.
203. Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T. Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3d constructs. J Cell Physiol 2006; 207: 331-39.
204. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007; 358: 948-53.
205. Hung SC, Pochampally RR, Hsu SC, et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of cx3cr1 and cxcr4 and their engraftment in vivo. PLoS ONE 2007; 2:e416.
206. Potier E, Ferreira E, Andriamanalijaona R, et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007; 40: 1078-87.
207. Rosová I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008; 26: 2173-82.
208. Rochefort GY, Delorme B, Lopez A, et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006; 24: 2202-8.
209. Okuyama H, Krishnamachary B, Zhou YF, Nagasawa H, BoschMarce M, Semenza GL. Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem 2006; 281: 15554-63.
210. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J 2006; 20: 661-69.
211. Hare JM, Traverse JH, Henry TD, et al. A randomized, doubleblind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am College Cardiol 2009; 54: 2277-86.
212. Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 2007; 9: 167-71.
213. Chen S, Liu Z, Tian N, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18:552-56.
214. Katritsis DG, Sotiropoulou PA, Karvouni E, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Cathet Cardiovasc Intervent 2005; 65: 321-29.
215. Chen S-liang, Fang W-wang, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95.